Welcome on board!
Pharnext is an advanced clinical-stage biopharmaceutical company committed to developing novel innovative therapeutics for orphan and common diseases with high unmet medical need.
Our proprietary R&D platform, PLEOTHERAPY™, systematically leverages genomic big data and AI to identify synergistic combinations of approved drugs or NCEs to generate new therapeutics with the potential to safely and effectively target and treat diseases.
Date
Number of shares comprising the share capital
Theoretical number of voting rights
December 31, 2020
19,404,296*
23,689,515
*Including 2,355,000 new shares issued from the equity line financing with Kepler Cheuvreux announced on November 19th 2019..
Stock Market
Euronext Growth Paris
Mnemo
ALPHA
Bloomberg
ALPHA/FR – Reuters: ALPHA.PA
ISIN Code
FR0011191287
Closing date
31 December
First day of trading
18 July 2016
Number of shares
19,404,296
Indices
EnterNext© PEA-PME 150,
Euronext Growth All-Share, Next Biotech, PEA
Liquidity contract
Kepler Cheuvreux
Eligible to PEA-PME (French fiscal advantage)
Share price
The analysts listed on the right follow PHARNEXT. Any opinions, estimates or forecasts made by these analysts regarding PHARNEXT are individual and do not represent opinions, forecasts or predictions of PHARNEXT's management. PHARNEXT does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. Requests for copies of analyst reports should be directly addressed to the above-mentioned analyst and institution.
Kepler Cheuvreux : Damien Choplain - email
Gilbert Dupont : Guillaume Cuvillier - email
Edison Group : Nathaniel Calloway - email
Initiation of coverage report*
R&D Day Event report*
* These hyperlinks to a third party website are provided for information only and do not constitute an endorsement of any content provided therein.
Pharnext Announces Financing of €11 Million Through a Capital Raise Subscribed by Existing Shareholders and a Convertible Bonds Issued to European Investors; European Investors Also Provide Indication of Interest for an Additional Amount of up to €25 Million in Convertible Bonds
Pharnext Provides an Update on its Pivotal Clinical Development Program in Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’)
Pharnext 2019 Universal Registration Document Approved by AMF
Letter to Shareholders from Dr. David Horn Solomon, Chief Executive Officer
Pharnext announces 2020 half-year results
Corporate presentation
Pharnext Corporate Presentation
Pharnext Corporate Presentation - JP Morgan Webcast
Presentation of the R&D Day Event
Highlights of the R&D Day Event
General meeting
General meeting
General meeting
General meeting
Letter to shareholders
Letter to Shareholders
Letter to Shareholders n°4
Letter to Shareholders n°3
Letter to Shareholders n°2
Letter to Shareholders n°1
Regulated Information
YE 2020 Half-year liquidity contract report (only available in French)
2019 Universal Registered Document
IFRS Financial report first-half 2020
2020 Half-year liquidity contract report (only available in French)
Auditors’ report on Financial year 2019 - French Gaap (only available in French)
Mary-Jane Elliott
Sukaina Virji
Alexandra Harrison
Mary-Jane Elliott
Sukaina Virji
Alexandra Harrison